5.335
전일 마감가:
$6.16
열려 있는:
$6.205
하루 거래량:
9.30M
Relative Volume:
3.06
시가총액:
$474.84M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+2.62%
1개월 성능:
+6.90%
6개월 성능:
+48.13%
1년 성능:
+153.64%
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ATYR
Atyr Pharma Inc
|
5.335 | 518.90M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
467.40 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.91 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.69 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.00 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
305.31 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-18 | 개시 | Leerink Partners | Outperform |
2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
2024-10-04 | 개시 | Wells Fargo | Overweight |
2024-09-05 | 개시 | Jefferies | Buy |
2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
2021-09-21 | 개시 | Piper Sandler | Overweight |
2021-05-10 | 개시 | Laidlaw | Buy |
2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-03-04 | 개시 | ROTH Capital | Buy |
2020-03-02 | 개시 | Oppenheimer | Outperform |
2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2017-09-07 | 개시 | Piper Jaffray | Overweight |
2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2015-12-16 | 개시 | Citigroup | Neutral |
2015-06-01 | 개시 | Citigroup | Buy |
2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade
Is it the right time to buy aTyr Pharma Inc. stockAchieve breakthrough gains with smart trades - jammulinksnews.com
What are the technical indicators suggesting about aTyr Pharma Inc.Free Consultation - jammulinksnews.com
What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - jammulinksnews.com
How does aTyr Pharma Inc. generate profit in a changing economyRapid wealth accumulation - jammulinksnews.com
What makes aTyr Pharma Inc. stock price move sharplyUnlock powerful stock screening techniques - jammulinksnews.com
What is aTyr Pharma Inc. company’s growth strategyBuild a portfolio with strong long-term growth - jammulinksnews.com
How volatile is aTyr Pharma Inc. stock compared to the marketUnstoppable trading performance - jammulinksnews.com
Is aTyr Pharma Inc. a good long term investmentUnprecedented market success - PrintWeekIndia
Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - jammulinksnews.com
RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga
aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest
aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks
What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional
aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire
What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com
aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study - TipRanks
First-Ever Global Phase 3 Trial for Sarcoidosis Treatment Reaches Major Milestone with 268 Patients - Stock Titan
aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Atyr Pharma Inc 주식 (ATYR) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
자본화:
|
볼륨(24시간):